Braun Stacey Associates Inc. Sells 1,391 Shares of Danaher Co. (NYSE:DHR)

Braun Stacey Associates Inc. decreased its position in shares of Danaher Co. (NYSE:DHR) by 1.6% in the 4th quarter, Holdings Channel reports. The fund owned 84,616 shares of the conglomerate’s stock after selling 1,391 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Danaher were worth $19,424,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of DHR. FMR LLC grew its position in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after acquiring an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after acquiring an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. increased its holdings in Danaher by 0.6% during the 4th quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after acquiring an additional 9,942 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 11.10% of the stock is currently owned by insiders.

Danaher Stock Performance

Shares of NYSE:DHR opened at $206.66 on Tuesday. The stock has a market capitalization of $149.26 billion, a P/E ratio of 39.14, a PEG ratio of 2.68 and a beta of 0.83. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The firm has a fifty day simple moving average of $229.53 and a two-hundred day simple moving average of $249.13.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the firm earned $2.09 earnings per share. On average, analysts expect that Danaher Co. will post 7.67 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date was Friday, December 27th. Danaher’s payout ratio is presently 20.45%.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent analyst reports. Robert W. Baird reduced their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Jefferies Financial Group cut their price target on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday, January 29th. Raymond James reissued a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.